197367-75-2

Usage

Uses

Used in Pharmaceutical Industry:
7-Oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxylic acid is used as an intermediate in the synthesis of pharmaceutical compounds for its potential biological activities. Its anti-inflammatory and anti-cancer properties make it a valuable component in the development of new drugs and pharmaceutical agents.
Used in Drug Development:
7-Oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxylic acid is used as a building block in the preparation of various pharmacologically active compounds. Its role in drug development is crucial, as it contributes to the creation of innovative and effective treatments for various medical conditions.

InChI:InChI=1/C7H5N3O3/c11-6-4(7(12)13)3-8-5-1-2-9-10(5)6/h1-3,8H,(H,12,13)

Upstream product

• 29274-18-8 ethyl 7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxylate 
• 29274-17-7 diethyl 2-((1H-pyrazol-5-ylamino)methylene)malonate 

Downstream Products

• 29274-23-5 4,7-dihydropyrazolo<1,5-a>pyrimidin-7-one 
• 1161024-91-4 N-(2,4-di-tert-butyl-5-hydroxyphenyl)-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide 
• 877173-84-7 3-bromo-7-chloropyrazolo[1,5-a]pyrimidine 
• 58347-49-2 7-chloropyrazolo[1,5-a]pyrirnidine 

Relevant academic research and scientific papers

Acid Derivatives of Pyrazolo[1,5-a]pyrimidine as Aldose Reductase Differential Inhibitors

Aldose reductase (AKR1B1), the key enzyme of the polyol pathway, plays a crucial role in the development of long-term complications affecting diabetic patients. Nevertheless, the expedience of inhibiting this enzyme to treat diabetic complications has fai

Novel Hinge-Binding Motifs for Janus Kinase 3 Inhibitors: A Comprehensive Structure-Activity Relationship Study on Tofacitinib Bioisosteres

The Janus kinases (JAKs) are a family of cytosolic tyrosine kinases crucially involved in cytokine signaling. JAKs have been demonstrated to be valid targets in the treatment of inflammatory and myeloproliferative disorders, and two inhibitors, tofacitinib and ruxolitinib, recently received their marketing authorization. Despite this success, selectivity within the JAK family remains a major issue. Both approved compounds share a common 7H-pyrrolo[2,3-d]pyrimidine hinge binding motif, and little is known about modifications tolerated at this heterocyclic core. In the current study, a library of tofacitinib bioisosteres was prepared and tested against JAK3. The compounds possessed the tofacitinib piperidinyl side chain, whereas the hinge binding motif was replaced by a variety of heterocycles mimicking its pharmacophore. In view of the promising expectations obtained from molecular modeling, most of the compounds proved to be poorly active. However, strategies for restoring activity within this series of novel chemotypes were discovered and crucial structure-activity relationships were deduced. The compounds presented may serve as starting point for developing novel JAK inhibitors and as a valuable training set for in silico models.

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The present invention relates to modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof of formula (I), including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention

Synthesis of pyrazolo[1,5-α]pyrimidinone regioisomers

(Chemical Equation Presented) This work describes two distinct routes to prepare pyrazolo-[1,5-α]pyrimidin-7-ones and two distinct routes to prepare pyrazolo[1,5-α]pyrimidin-5-ones. Use of 1,3-dimethyluracil as the electrophile in the preparation of the p